On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
1hon MSNOpinion
Unfortunately, an FDA policy — specifically the Risk Evaluation and Mitigation Strategies (REMS) program — has been largely ...
Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
(OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative ...
Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...
Zacks.com on MSN3d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Related: Bristol Myers's stock pops as earnings top estimates and company raises guidance In September, Bristol Myers's shares rose after the FDA approved Cobenfy. The drug, previously called KarXT, ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback